Drug Profile
Research programme: neurodegenerative disorder therapeutics - NeuroProfile
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator NeuroProfile
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Germany
- 28 Sep 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in Germany
- 11 Aug 2016 Preclinical trials in Alzheimer's disease in Germany (unspecified route)